FACULTY
Mario Castro, MD, MPH
Chief, Pulmonary, Critical Care and Sleep Medicine
Vice Chair for Clinical and Translational Research
Director, Frontiers: University of Kansas Clinical & Translational Science Institute
Director, Rainbow Clinical Trials Science Unit
University of Kansas School of Medicine
Kansas City, KS
Geoffrey C. Wall, PharmD, FCCP, BCPS
John R. Ellis Distinguished Chair of Pharmacy Practice
Professor of Clinical Sciences
Director, Drake Drug Information Center
Drake University College of Pharmacy and Health Sciences
Internal Medicine Clinical Pharmacist
Iowa Methodist Medical Center
Des Moines, IA
PROGRAM OVERVIEW
This enduring activity will cover the treatment and management of patients with moderate-to-severe asthma.
TARGET AUDIENCE
This CME initiative is designed to meet the educational needs of US-based managed care professionals who manage or are involved with the care of patients with moderate-to-severe asthma.
LEARNING OBJECTIVES
After completing the CME activity, learners should be better able to:
- Discuss the patient and healthcare system burdens associated with asthma
- Explain how the underlying molecular pathophysiology of moderate-to-severe asthma informs targeted biologic therapies
- Apply current medical committee guidelines and recommendations for the management of patients with moderate-to-severe asthma in clinical practice
- Utilize findings from clinical trials of biologic therapies as add-on treatments in the maintenance setting for patients with moderate-to-severe asthma
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this online activity for a maximum of 1.0 AMA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the online activity.
CNE ACCREDITATION STATEMENT
Ultimate Medical Academy/Complete Conference Management (CCM) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.
NURSING CREDIT INFORMATION
Purpose: This program would be beneficial for nurses involved in the care of patients with moderate-to-severe asthma.
Credits: 1.0 ANCC Contact Hour.
Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Med Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Pharmacists and Pharmacy Technicians
Amedco LLC designates this activity for a maximum of 1.0 knowledge-based CPE contact hour.
NOTE: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of your participation in the activity to meet the deadline for submission to CPE Monitor.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF CONFLICTS OF INTEREST
Mario Castro, MD, MPH serves on the speaker bureau for AstraZeneca, Genentech, GlaxoSmithKline, Regeneron, Sanofi, and Teva. He receives fees as a consultant for Genentech, Teva, Sanofi-Aventis and Novartis. He contracted research from AstraZeneca, GlaxoSmithKline, Pulmatrix, Sanofi-Aventis and Shinogi. He receives grant funding from AstraZeneca, GlaxoSmithKline, Pulmatrix, and Sanofi-Aventis.
Geoffrey C. Wall, PharmD, FCCP, BCPS serves on the speaker bureau for Janssen Pharmaceuticals and Tetraphase Pharmaceuticals.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.
Staff, Planners, and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Felecia Beachum, Program Manager for Med Learning Group, has nothing to disclose.
Marcello Morgan, MD, MPH, Medical Director for Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
Brianna Hanson, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During this lecture, the faculty may mention the use of medications for both FDA-approved and nonapproved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME credit for this online activity. To receive CME/CNE credit participants must:
- Read the CME/CNE information and faculty disclosures.
- Participate in the online activity.
- Submit the evaluation form to Med Learning Group.
You will receive your certification as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making skills before applying any information, whether provided here or by others, for any professional use.
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected].
For CME questions, please contact Med Learning Group at [email protected].
RELEASE DATE: May 11, 2021
EXPIRATION DATE: May 11, 2022
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
ENDURING LEARNER NOTIFICATION
Med Learning Group
Targeted Approaches to the Management of Moderate-to-Severe Asthma: Implications for Managed Care – An Innovative View – ENDURING
May 11, 2021 – May 11, 2022
Online
Acknowledgement of Financial Commercial Support
Sanofi Genzyme and Regeneron Pharmaceuticals
Acknowledgement of In-Kind Commercial Support
No in-kind commercial support was received for this educational activity.
Satisfactory Completion
Learners must complete an evaluation form to receive a certificate of completion. You must attend the entire webinar as partial credit is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.
Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Med Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Pharmacists and Pharmacy Technicians
Amedco LLC designates this activity for a maximum of 1.0 knowledge-based CPE contact hours.
UAN(s): JA4008163-9999-21-073-H04-P / JA4008163-9999-21-073-H04-T
NOTE: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of your participation in the activity to meet the deadline for submission to CPE Monitor.
Objectives – After Attending This Program You Should Be Able To
- Discuss the patient and healthcare system burdens associated with asthma.
- Explain how the underlying molecular pathophysiology of moderate-to-severe asthma informs targeted biologic therapies.
- Apply current medical committee guidelines and recommendations for the management of patients with moderate-to-severe asthma in clinical practice.
Disclosure of Conflict of Interest
The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1-‐6.2, 6.5).
All individuals in a position to control the content of CE are listed below:
Name | Relationship: Commercial Interest |
---|---|
Felecia Beachum | NA |
Mario Castro | Speaker Bureau: AstraZeneca, Genentech, GlaxoSmithKline, Regeneron, Sanofi. Consultant: Genentech, Teva, Sanofi-Aventis and Novartis. Contracted Research: AstraZeneca, GlaxoSmithKline, Pulmatrix, Sanofi-Aventis, Shinogi. |
Matthew Frese | NA |
Christina Gallo | NA |
Brianna Hanson | NA |
Scott McGee-Plys | NA |
Marcello Morgan | NA |
Geoffrey C. Wall | Speaker Bureau: Janssen Pharmaceuticals, Tetraphase Pharmaceuticals |
Lauren Welch | NA |
How to Get Your Certificate
- Go to http://mlg.cmecertificateonline.com
- Click on “Targeted Approaches to the Management of Moderate-to-Severe Asthma: Implications for Managed Care – An Innovative View – ENDURING” link.
- Complete the post-test, click the provided link to go to the online evaluation site.
- Evaluate the meeting, click the provided link to open your credit certificate.
- Print/save all pages of your certificate for your records.
Questions?
Email [email protected]
Copyright © 2021 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.